The Role of Early Diagnosis and Intervention in Improving Outcomes for Lung Cancer
DOI:
https://doi.org/10.62497/IRABCS.2024.54Keywords:
lung cancer, early diagnosis, low-dose computed tomography, overall survival, quality of life, treatment-related adverse eventsAbstract
Introduction : For lung cancer patients, early diagnosis and treatments are essential to battering outcomes. The objective of this world is to compare early diagnosis vs late diagnosis in terms of overall survival ,progression _free survival, quality of life and adverse events associated to treatment.
Methodology: A Prospective cohort trial of seventy_ eight lung cancer patients was Conducted at Hayatabad Medical Complex in Peshawar from December 2021 to March 2024. 39 patients had early diagnosis (n=39) while 39 received late diagnosis(n=39) . Low_ dose Computed Tomography (DCT) screening and prompt symptom presentation lead to early diagnosis; incidental or symptomatic results were the basis for late diagnosis. Overall Survival(OS) , progression_ free survival (PFS), quality of life(QoL) , and frequency of serious adverse events associated to therapy were the outcomes.
Results: At a median 'OS of 38 months compared to 14 months in the late diagnosis group (p<0.001) and median PFS of 34 months compared to 10 months(p<0.001), the early diagnosis group showed noticeably superior results. At 12 months, 'the early diagnosis group had a better QoL scores' a mean global health status of 75 compared to 55(p<0.01). Early diagnosis group (18%) had a lower frequency of serious adverse effects than did the late diagnosis group(45%).
Conclusion: In patients with lung cancer, early detection and intervention greatly increases survival rates, prolong intervals without progression, improves quality of life, and lower serious side effects associated to therapy. The results emphasized the need of early diagnosis techniques and efficient screening programs in the treatment of lung cancer.
Keywords: lung Cancer, early diagnosis, low dose computed tomography, overall survival, progression free survival, quality of life, treatment related adverse events
Downloads
References
References
⦁ Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC, Han PK. Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review. Lung cancer. 2017 Oct 1;112:156-64.
⦁ Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open biology. 2017 Sep 6;7(9):170070.
⦁ Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. International journal of molecular sciences. 2021 Aug 12;22(16):8661.
⦁ Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ. Biomarkers in lung cancer screening: achievements, promises, and challenges. Journal of Thoracic Oncology. 2019 Mar 1;14(3):343-57.
⦁ Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nature reviews Clinical oncology. 2021 Mar;18(3):135-51.
⦁ Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, Hoo GS, Detterbeck FC. Screening for lung cancer: CHEST guideline and expert panel report. Chest. 2018 Apr 1;153(4):954-85.
⦁ de Koning HJ, van Der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JW, Weenink C, Yousaf-Khan U, Horeweg N, van’t Westeinde S. Reduced lung-cancer mortality with volume CT screening in a randomized trial. New England journal of medicine. 2020 Feb 6;382(6):503-13.
⦁ Xie Y, Meng WY, Li RZ, Wang YW, Qian X, Chan C, Yu ZF, Fan XX, Pan HD, Xie C, Wu QB. Early lung cancer diagnostic biomarker discovery by machine learning methods. Translational oncology. 2021 Jan 1;14(1):100907.
⦁ Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan 25;553(7689):446-54.
⦁ Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, Sverzellati N, Sozzi G, Corrao G, Marchianò A. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Annals of Oncology. 2019 Jul 1;30(7):1162-9.
⦁ Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature medicine. 2021 Aug;27(8):1345-56.
⦁ Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer discovery. 2017 Dec 1;7(12):1394-403.
⦁ Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, Nakamura M, Harris RJ, French E, Hoffmann RM, Williams IP. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Frontiers in immunology. 2019 Mar 19;10:453.
⦁ Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nature Reviews Disease Primers. 2021 Jan 14;7(1):3.
⦁ Prasad VK, Cifu AS. Ending medical reversal: improving outcomes, saving lives. Johns Hopkins University Press; 2019 May 14.
⦁ Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, Esener S, Fitzgerald RC, Gambhir SS, Kuhn P, Rebbeck TR. Early detection of cancer. Science. 2022 Mar 18;375(6586):eaay9040.
⦁ Basumallik N, Agarwal M. Small cell lung cancer. InStatPearls [internet] 2023 Jul 10. StatPearls Publishing.
⦁ Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treatment Reviews. 2019 Jul 1;77:20-8.
⦁ Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirology. 2020 Nov;25:61-71.
⦁ Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer epidemiology, biomarkers & prevention. 2019 Oct 1;28(10):1563-79.
⦁ Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in non–small cell lung cancer: facts and hopes. Clinical Cancer Research. 2019 Aug 1;25(15):4592-602.
⦁ Roointan A, Mir TA, Wani SI, Hussain KK, Ahmed B, Abrahim S, Savardashtaki A, Gandomani G, Gandomani M, Chinnappan R, Akhtar MH. Early detection of lung cancer biomarkers through biosensor technology: A review. Journal of pharmaceutical and biomedical analysis. 2019 Feb 5;164:93-103.
Downloads
Published
License
Copyright (c) 2024 Adil Saeed, Faiz Muhammad , Jawad Ahmad, Haseeb Akhtar, Muhammad Adeel , Adnan Ahmad (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright to their work published in the IRABCS journal under the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY-NC-ND 4.0).
![](<img src="https://assets.crossref.org/logo/crossref-logo-landscape-200.svg" width="200" height="68" alt="Crossref logo">){kind=logo}
